Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you approach patients with lymph node only recurrences in the setting of previously resected colon cancer that are not amenable to biopsy?
Do we wait and watch vs start treatment based on ctDNA results?
Related Questions
What second-line therapy would you offer a patient with metastatic colon cancer with HER2 IHC 3+ amplification and KRAS G12D mutation whose disease progressed on FOLFOX?
Are there long-term toxicity and QOL considerations for patients receiving nivo/ipi compared to checkpoint monotherapy that would impact your treatment decisions for first line metastatic MSI-H/dMMR CRC?
What factors do you use when considering the addition of celecoxib to adjuvant chemotherapy for patients with stage III colon cancer, given CALGB/SWOG 80702 trial results?
With recent PFS data from LEAP-012 and Emerald-1, do you routinely offer for patients with intermediate BCLC stage HCC undergoing TACE or TARE systemic therapy (pembro/lenva or durve/bev)?
What is your institutional practice for neoadjuvant therapy prior to transplanting cholangiocarcinoma?
How should immunotherapy be incorporated into the treatment strategy for patients with resectable stage III microsatellite instability–high (MSI-H) or mismatch-repair-deficient (dMMR) extrahepatic cholangiocarcinoma?
Do you regularly incorporate oral cryotherapy in your practice for patients receiving oxaliplatin to decrease the risk of thermal hyperalgesia?
Is there any circumstance where you would consider bevacizumab in patients with locally advanced colorectal cancer with rectouterine fistula?
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
Would you offer postoperative RT for pT2pN0 rectal cancer with close distal margin (within 2 mm) and only 6 lymph nodes obtained from surgery?